SARTORIUS AG |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 228 EUR | +5.56% |
|
+3.21% | -14.77% |
| Apr. 24 | SARTORIUS VORZUEGE : Gets a Buy rating from Berenberg | ZD |
| Apr. 23 | SARTORIUS VORZUEGE : DZ Bank gives a Sell rating | ZD |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- With an expected P/E ratio at 77.74 and 52.41 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -14.77% | 19.08B | - | ||
| -46.21% | 2.65B | C+ | ||
| +18.15% | 1.87B | - | - | |
| -3.12% | 1.61B | - | ||
| +22.59% | 1.21B | B+ | ||
| -10.69% | 1.02B | - | ||
| -20.89% | 905M | - | C- | |
| -6.85% | 716M | - | ||
| -18.10% | 682M | B+ | ||
| +3.77% | 480M | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- SRT3 Stock
- SRT Stock
- Ratings Sartorius AG
